drugset / Trial / NCT05515588

A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body

NCT05515588

Phase 1 Completed 14 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The trial is intended to investigate the basic pharmacokinetics, excretion pathways and metabolism of BI 690517 and its metabolites.

Timeline

Start
2022-09-19
Primary completion
2022-11-17
Completion
2022-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Vicadrostat Small molecule Oral

Indications

No indication recorded.